In prostate cancer, loss of REST is associated with the emergence of the most aggressive form of the disease, NEPC, featuring its known characteristics, notably the loss of AR signaling, and induction of genes related to neuroendocrine differentiation, such as CHGA, a target gene of REST [74]. This evidence concerns the gene AR and prostate carcinoma.